北京大学学报(医学版) ›› 2021, Vol. 53 ›› Issue (3): 555-559. doi: 10.19723/j.issn.1671-167X.2021.03.019

• 论著 • 上一篇    下一篇

克罗恩病患者疾病经济负担现状与相关因素

周吴平1,穆楠2,简伟研1,Δ(),王化虹3,Δ()   

  1. 1.北京大学公共卫生学院社会医学与卫生事业管理系,北京 100191
    2.中卫护理信息管理研究院,北京 100086
    3.北京大学第一医院消化内科,北京 100034
  • 收稿日期:2021-03-01 出版日期:2021-06-18 发布日期:2021-06-16
  • 通讯作者: 简伟研,王化虹 E-mail:jianweiyan@bjmu.edu.cn;wwwanghuahong@163.com

Economic burden and factors associated with Crohn’s disease

ZHOU Wu-ping1,MU Nan2,JIAN Wei-yan1,Δ(),WANG Hua-hong3,Δ()   

  1. 1. Department of Health Policy and Management, Peking University School of Public Health, Beijing 100191, China
    2. Zhongwei Institute of Nursing Information, Beijing 100086, China
    3. Department of Gastroenterology,Peking University First Hospital, Beijing 100034, China
  • Received:2021-03-01 Online:2021-06-18 Published:2021-06-16
  • Contact: Wei-yan JIAN,Hua-hong WANG E-mail:jianweiyan@bjmu.edu.cn;wwwanghuahong@163.com

摘要:

目的: 研究克罗恩病患者的疾病经济负担及其相关因素,为降低个人负担、完善医保报销政策提供意见参考。方法: 采用横断面调查的研究方法,根据卫生服务研究基本原理和原则自行制作问卷,对上海市志愿者服务基金会平台所服务的克罗恩病患者进行调查。搜集患者基本特征、接受治疗的方案、过去一年发生的治疗费用等信息,运用描述性统计分析克罗恩病患者过去一年治疗疾病的住院、门诊费用构成,在此基础上进一步构建对数-线性模型,分析克罗恩病患者经济负担的相关因素。结果: 研究发放820份问卷,回收799份问卷,其中有效问卷797份。男性528例(66.25%),女性269例(33.75%),患者平均年龄(34.02±11.49)岁,年龄集中在18~39岁(510例,63.99%),平均患病年限(5.58±5.13)年。有10.7%的患者并未接受持续治疗,持续治疗的患者平均每年治疗费用54 246元,其中个人支付30 279元(55.8%),统筹支付23 966元(44.2%),个人经济负担接近2020年全国居民人均可支配收入32 189元(94.1%),超过2016年我国2型糖尿病患者每年治疗费用8 245元。门诊与住院分布上,住院每年平均费用31 092元,其中个人自付费用14 673元(48.5%),统筹支付费用16 418元(51.5%);门诊每年平均费用23 154元,个人自付15 606元(65.1%),统筹支付费用7 548元(34.9%),门诊自付费用高于住院自付费用。对数-线性模型回归结果表明,每年治疗总费用与患病年限(β=0.03,P<0.01)、患并发症(β=-0.68,P<0.01)、接受手术治疗(β=0.52,P<0.01)、使用免疫抑制剂(β=0.51,P<0.01)、年门诊就诊次数(β=0.02,P<0.05)、年住院次数(β=0.08,P<0.01)有关。结论: 克罗恩病患者每年疾病经济负担较重,且随着患病年限的增长而明显升高,超过了糖尿病等慢性疾病。患者个人经济负担接近全国居民人均可支配收入,医疗保障部门应该制定相关政策,降低患者经济负担,针对患者门诊个人经济负担超过住院个人经济负担的特点,将克罗恩病纳入门诊特殊病种是未来可以考虑的措施。

关键词: 克罗恩病, 患病代价, 医保费用, 卫生政策

Abstract:

Objective: To study the economic burden of Crohn’s disease and its related factors, and to provide opinions for reducing personal burden and improving reimbursement policy. Methods: Using a cross-sectional method, a self-created questionnaire based on the basic principles of health services research was used to survey Crohn’s disease patients served by the Shanghai volunteer service foundation platform. Information collected included basic characteristics, therapy, and medical costs related to Crohn’s disease in the past 12 months. Descriptive statistics were used to analyse the composition of inpatient and outpatient costs of Crohn’s disease for treatment of the disease in the past year. Further, a logarithm-linear model was constructed to analyse the factors associated with the financial burden of Crohn’s disease. Results: In the study, 820 questionnaires were distributed and 799 questionnaires were returned, of which 797 were valid. There were 528 (66.25%) males and 269 (33.75%) females. The mean age of the patients was (34.02±11.49) years, with a concentration between 18-39 years (510 cases, 63.99%) and a mean disease duration of (5.58±5.13) years. 10.7% of the patients did not receive continuous treatment, and the average annual treatment cost for the patients with continuous treatment was 54 246 Yuan, of which 30 279 Yuan (55.8%) was paid by the individuals and 23 966 Yuan (44.2%) was paid by the insurance. The personal financial burden was close to the national per capita disposable income in 2020, which was 32 189 Yuan (94.1%), exceeding the annual cost for type 2 diabetes in China in 2016, 8 245 Yuan. In terms of the distribution of outpatient and inpatient services, the average annual cost of inpatient services was 31 092 Yuan, of which 14 673 Yuan (48.5%) was paid out of pocket by the individuals and 16 418 Yuan (51.5%) was paid by the insurance; the average annual cost of outpatient services was 23 154 Yuan, of which 15 606 Yuan (65.1%) was paid out of po-cket by the individuals and 7 548 Yuan (34.9%) was paid by the insurance. The personal burden of outpatient care was higher than of inpatient care. The regression results of the logarithm-linear model showed that the total annual treatment cost was related to the duration of illness (β=0.03, P<0.01), having complications (β=-0.68, P<0.01), receiving surgical treatment (β=0.52, P<0.01), using immunosuppressive drugs (β=0.51, P<0.01), annual outpatient visits (β=0.02, P<0.05), and number of hospitalizations per year (β=0.08, P<0.01). Conclusion: The annual financial burden for patients with Crohn’s disease is heavy and rises significantly with the duration of illness, exceeding that of chronic diseases such as diabetes. The personal financial burden is close to the national per capita disposable income, and the medical security department should develop policies to reduce the financial burden. The inclusion of Crohn’s disease as a special outpatient disease is a possible measure that could be considered in response to the fact that the outpatient personal financial burden is heavier than the inpatient’s.

Key words: Crohn’s disease, Cost of illness, Health care costs, Health policy

中图分类号: 

  • R191

表1

克罗恩病患者基本信息"

Items n (%)
Gender
Male 528 (66.3)
Female 269 (33.8)
Age
0 year- 37 (4.6)
18 years- 510 (64.0)
40 years- 188 (23.6)
60 years- 62 (7.8)
Complications
With complication 97 (12.2)
No complication 700 (87.8)
Activity of disease
Active 108 (13.6)
Remission 479 (60.1)
Unclear 210 (26.4)
Length of illness
0 year- 113 (14.2)
1 year- 194 (24.3)
3 years- 151 (19.0)
5 years- 339 (42.5)
Total 797 (100.0)

表2

克罗恩病患者未接受持续治疗的原因"

Items n (%)
Side effects 14 (16.5)
Treatment is too expensive 15 (17.7)
Disease cannot be cured 18 (21.2)
Dissatisfaction with the efficacy of the treatment 2 (2.4)
Subjective discontinuation 22 (25.9)
Other 14 (16.5)
Total 85 (100.0)

表3

不同疾病时期克罗恩病患者使用治疗方案分布"

Treatment Active, n (%) Remission, n (%) Unclear, n (%) Total, n (%)
Surgical 11 (10.2) 431 (90.0) 35 (16.7) 96 (12.0)
Drug 89 (82.4) 50 (10.4) 149 (71.0) 669 (83.9)
Biological agents 58 (53.7) 246 (51.4) 82 (39.0) 386 (48.4)
Nutritional agents 46 (42.6) 146 (30.5) 56 (26.7) 248 (31.1)
Immunosuppressants 14 (13.0) 145 (30.3) 38 (18.1) 197 (24.7)
Aminosalicylates 7 (6.5) 28 (5.8) 13 (6.2) 48 (6.0)
Glucocorticoids 10 (9.3) 12 (2.5) 16 (7.6) 38 (4.8)
Total 108 (100.0) 479 (100.0) 210 (100.0) 797 (100.0)

表4

克罗恩病患者每年经济负担"

Items Out of pocket Reimbursement Total
Inpatient costs 14 673±9 297 16 418±11 296 31 091±24 211
outpatient costs 15 606±9 109 7 548±5 796 23 154±16 709
Total 30 279±25 116 23 966±18 075 54 245±48 677

表5

克罗恩病患者每年治疗费用多元回归结果"

Independent variable ln(Total annual cost)
Coefficient Standard error P
Gender
Male -0.17 0.12 0.17
Age
18-39 years 0.21 0.26 0.41
39-59 years 0.33 0.26 0.21
>59 years 0.57 0.38 0.13
Length of illness 0.03 0.01 0.01
With complication -0.68 0.24 0.01
Received surgical treatment 0.52 0.18 <0.001
Glucocorticoids -0.24 0.23 0.29
Aminosalicylates -0.37 0.23 0.10
Immunosuppressants 0.51 0.17 <0.001
Biological agents 0.21 0.13 0.11
Nutritional agents 0.01 0.13 0.93
Number of outpatient visit 0.02 0.01 0.05
Number of hospitalizations 0.08 0.03 <0.001
[1] 吴开春, 梁洁, 冉志华, 等. 炎症性肠病诊断与治疗的共识意见(2018年·北京)[J]. 中国实用内科杂志, 2018,38(9):796-813.
[2] Adamina M, Bonovas S, Raine T, et al. ECCO guidelines on therapeutics in Crohn’s disease: Surgical treatment[J]. J Crohns Colitis, 2020,14(2):155-168.
doi: 10.1093/ecco-jcc/jjz187 pmid: 31742338
[3] 中华医学会消化病学分会炎症性肠病学组, 中华医学会肠外与肠内营养学分会胃肠病与营养协作组. 炎症性肠病营养支持治疗专家共识(第二版)[J]. 中华炎性肠病杂志(中英文), 2018,2(3):154-172.
[4] Lichtenstein GR, Shahabi A, Seabury SA, et al. Lifetime economic burden of Crohn’s disease and ulcerative colitis by age at diagnosis[J]. Clin Gastroenterol Hepatol, 2020,18(4):889-897.
doi: 10.1016/j.cgh.2019.07.022
[5] Yu Q, Zhu C, Feng S, et al. Economic burden and health care access for patients with inflammatory bowel diseases in China: Web-based survey study[J]. J Med Internet Res, 2021,23(1):e20629.
doi: 10.2196/20629
[6] Mak WY, Zhao M, Ng SC, et al. The epidemiology of inflammatory bowel disease: East meets west[J]. J Gastroenterol Hepatol, 2020,35(3):380-389.
doi: 10.1111/jgh.v35.3
[7] Ng SC, Leung WK, Shi HY, et al. Epidemiology of inflammatory bowel disease from 1981 to 2014: Results from a territory-wide population-based registry in Hong Kong[J]. Inflamm Bowel Dis, 2016,22(8):1954-1960.
doi: 10.1097/MIB.0000000000000846
[8] Pellino G, Keller DS, Sampietro GM, et al. Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): Crohn’s disease[J]. Tech Coloproctol, 2020,24(5):421-448.
doi: 10.1007/s10151-020-02183-z pmid: 32172396
[9] Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: Medical treatment[J]. J Crohns Colitis, 2020,14(1):4-22.
doi: 10.1093/ecco-jcc/jjz180 pmid: 31711158
[10] Wang YF, Ouyang Q, Hu RW. Progression of inflammatory bowel disease in China[J]. J Dig Dis, 2010,11(2):76-82.
doi: 10.1111/cdd.2010.11.issue-2
[11] Ng SC, Kaplan GG, Tang W, et al. Population density and risk of inflammatory bowel disease: A prospective population-based study in 13 countries or regions in Asia-Pacific[J]. Am J Gastroenterol, 2019,114(1):107-115.
doi: 10.1038/s41395-018-0233-2
[12] Chen H, Shi J, Pan Y, et al. Cost-effectiveness of reimbursing infliximab for moderate to severe Crohn’s disease in China[J]. Adv Ther, 2020,37(1):431-449.
doi: 10.1007/s12325-019-01150-x
[13] Mao W, Yip CW, Chen W. Complications of diabetes in China: Health system and economic implications[J]. BMC Public Health, 2019,19(1):269. doi: 10.1186/s12889-019-6569-8.
doi: 10.1186/s12889-019-6569-8
[14] 李春燕, 简伟研. 中老年人心血管疾病经济负担——基于中国健康与养老追踪调查的实证分析[J]. 中国卫生政策研究, 2017,10(5):75-80.
[15] 袁鸿绯, 郑武, 徐根荣. 台州市区职工医保特殊病门诊支出分析[J]. 中国医疗保险, 2017(10):54-58.
[16] 段承阿鑫, 常峰, 路云. 我国各省城镇职工基本医疗保险门诊特殊疾病政策比较研究[J]. 中国卫生事业管理, 2017,34(5):342-345.
[1] 周玉博, 罗树生, 李宏田, 高燕秋, 刘建蒙. 1996年至2013年中国婚前医学检查率变化情况[J]. 北京大学学报(医学版), 2015, 47(3): 437-442.
[2] 刘明, 孙利华, 刘国恩. 中国城镇居民5种慢性疾病的经济负担和经济风险[J]. 北京大学学报(医学版), 2014, 46(5): 782-789.
[3] 张磊, 朱磊, 李志恒, 李金洲, 潘宏伟, 张少峰, 秦文华, 何丽华. 煤工尘肺住院患者疾病负担及其影响因素分析[J]. 北京大学学报(医学版), 2014, 46(2): 226-231.
[4] 谢铮, 刘培龙, 郭岩. 全球制定卫生领域后千年发展目标的行动、进展及启示[J]. 北京大学学报(医学版), 2013, 45(03): 495-498.
[5] 王富华, 谢铮, 吕敏, 邓瑛, 张拓红. 北京户籍老人免费流感疫苗接种情况及城乡差异分析[J]. 北京大学学报(医学版), 2013, 45(03): 432-436.
[6] 王友发, LIM Hyunjung, 吴杨. 全球慢性非传染病负担急剧增长及中国的现状[J]. 北京大学学报(医学版), 2012, 44(5): 688-693.
[7] 石洪兴, 吕军, 谢一萍, 王颖, 贾金忠, 苌凤水, 段琳, 孙梅, 王志锋, 郝模. 中国乡级卫生机构卫生服务需求弹性的研究[J]. 北京大学学报(医学版), 2010, 42(3): 264-269.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 赵磊, 王天龙 . 右心室舒张末期容量监测用于肝移植术中容量管理的临床研究[J]. 北京大学学报(医学版), 2009, 41(2): 188 -191 .
[2] 万有, , 韩济生, John E. Pintar. 孤啡肽基因敲除小鼠电针镇痛作用增强[J]. 北京大学学报(医学版), 2009, 41(3): 376 -379 .
[3] 张燕, 韩志慧, 钟延丰, 王盛兰, 李玲玲, 郑丹枫. 骨骼肌活组织检查病理诊断技术的改进及应用[J]. 北京大学学报(医学版), 2009, 41(4): 459 -462 .
[4] 林红, 王玉凤, 吴野平. 学校生活技能教育对小学三年级学生行为问题影响的对照研究[J]. 北京大学学报(医学版), 2007, 39(3): 319 -322 .
[5] 丰雷, 程嘉, 王玉凤. 注意缺陷多动障碍儿童的运动协调功能[J]. 北京大学学报(医学版), 2007, 39(3): 333 -336 .
[6] 李岳玲, 钱秋瑾, 王玉凤. 儿童注意缺陷多动障碍成人期预后及其预测因素[J]. 北京大学学报(医学版), 2007, 39(3): 337 -340 .
[7] . 书讯[J]. 北京大学学报(医学版), 2007, 39(3): 225 -328 .
[8] 牟向东, 王广发, 刁小莉, 阙呈立. 肺黏膜相关淋巴组织型边缘区B细胞淋巴瘤一例[J]. 北京大学学报(医学版), 2007, 39(4): 346 -350 .
[9] 张宏文, 丁洁, 王芳, 杨惠霞. 一例X连锁Alport综合征女性妊娠期随访[J]. 北京大学学报(医学版), 2007, 39(4): 351 -354 .
[10] 常杏芝, 卢红梅, 张月华, 秦炯. 以高血压与红斑肢痛为主要表现的汞中毒一例[J]. 北京大学学报(医学版), 2007, 39(4): 377 -380 .